The stock nobody wants to touch right now
Pull up the Zoetis (ZTS) chart and you’ll understand why most traders have already written this name off. A stock that traded above $246 in December 2021 is sitting at $75.35 today, down more than 69% from its all-time high. Four separate guidance cuts in the last thirteen months. A securities fraud class action with a lead plaintiff deadline of July 27, 2026. A flagship drug facing FDA safety scrutiny. This is not a “buy the dip and hope” post. It’s a look at why a serious long-term thesis, technical and fundamental, exists for ZTS to eventually work its way back toward the $310 area over the next several years, and why the discipline that keeps a trader solvent in a scalping account applies just as much to holding a beaten-down blue chip through the kind of drawdown it’s already shown it’s capable of.
Why this stock got left for dead
Zoetis is the largest pure-play animal health company in the world. Vaccines, parasiticides, diagnostics, dermatology treatments, for both livestock and companion animals. It’s the kind of business model that used to trade like a bond proxy: sticky demand, high margins, pricing power. Then the wheels came off.
Librela, the company’s canine osteoarthritis pain injection, started drawing FDA adverse-event scrutiny over neurological complications, and vet confidence in the drug eroded fast. Simparica Trio, one of the flagship flea and tick products, started losing share to a cheaper competitor. Apoquel and Cytopoint, the dermatology franchise that was supposed to be a growth engine, ran into new entrants undercutting on price just as pet owners across the Gen Z and Millennial cohorts started pulling back on vet visits altogether.
Management responded the way management usually responds when a controlled narrative starts slipping: guide down, then guide down again. Full-year guidance got cut on August 5, 2025, then again on November 4, 2025 to $124.46, then again on February 12, 2026 to $125.64, then the big one on May 7, 2026, a 21.5% single-day cut down to $87.31 that produced the stock’s worst trading day on record. A fifth cut followed in August 2026, with EPS guidance landing at $6.15 to $6.25 against a Street consensus of $6.87, driven largely by a 16% year-over-year decline in the Key Dermatology franchise. Layer a securities fraud class action covering the January 2025 to May 2026 period on top of that, and you get a stock that the market has decided is broken.
That’s the setup. Here’s the case that it isn’t.
The technical setup: this is exactly what a major bottoming structure looks like
The monthly chart tells a specific story once you draw a Fibonacci retracement from the 2013/2014 IPO-era low of $27.51 up to the December 2021 all-time high of $246.99. Current price at $75.35 is sitting almost precisely on the 78.6% retracement level ($75.46), the deepest level traders watch before a move is considered a full round trip back to origin. That’s not a random spot to be consolidating. It’s the last major technical shelf before a retracement stops being a “pullback” and starts being a “failure.”
The daily chart shows exactly what you’d expect price to do at that kind of level: it stopped falling. Since bottoming near $71.45 (the 52-week low), ZTS has spent months compressing sideways in the $71 to $85 range, building a base under a declining 50-day EMA and a longer moving average both still sitting overhead near $104. That’s not a bullish chart yet. It’s a chart that has stopped being a bearish one, which for a stock that’s been in freefall for two years is the first prerequisite for anything else to happen.
The extension side of the same Fibonacci drawing is where the $310 number actually comes from. Projecting beyond the all-time high using the same swing (the $27.51 low to the $246.99 high), the -27.2% extension level lands at $309.42. That’s not a made-up round number. It’s the same measured-move logic that shows up on every major reversal chart eventually: when a stock retraces almost the entirety of a multi-year advance and then finds support, the symmetrical extension on the other side of the original high becomes the level buyers are quietly targeting years in advance. AVAV, GOOGL, NVDA, and dozens of other multi-year turnaround names all have this same fingerprint in their charts, if you go back and look.
The fundamental engine: this isn’t a broken business, it’s a mispriced one
Here’s what a scared market misses when it dumps a stock 70%: it usually overshoots the business reality by a wide margin. Zoetis generated $9.467 billion in revenue for FY2025, up from $7.776 billion in FY2021, a 5.04% revenue CAGR through the entire crash period. Gross margin still sits at 72%, operating margin at 37%. Net income for FY2025 was $2.673 billion on diluted EPS of $6.02. This is a company that grew revenue and kept elite-tier margins while its stock price fell by more than two-thirds. That gap between “the business” and “the stock” is exactly where long-term swing setups come from.
The balance sheet backs it up. FY2025 operating cash flow was $2.904 billion, free cash flow was $2.283 billion, and management used that cash to buy back $3.235 billion in stock and pay $889 million in dividends, all while carrying a net debt to EBITDA ratio of 1.717 and posting a return on invested capital of 26.73% and a return on equity of 65.99%. Those aren’t the numbers of a company in structural decline. They’re the numbers of a company getting a discount multiple because the market is currently pricing in more bad news than the fundamentals justify.
That discount shows up plainly in the valuation. ZTS traded at a P/E of 57.15 back in FY2021 when the stock was near its all-time high. Today, with the stock down 69%, the trailing P/E sits at 12.41 and the FY2025 P/E is 20.9, with an EV/EBITDA multiple of 14.97. That’s roughly a 63% compression in the earnings multiple on top of the price decline itself. Even Wall Street’s own targets acknowledge the disconnect: 58.3% of covering analysts rate the stock bullish with zero bearish ratings, and the average price target sits at $104.08, with a high target of $160, both well above the current $75.35.
Doing the $310 math the boring way
Forget the chart for a second and build the number from earnings. Consensus estimates put FY2026 EPS at $7.41 and FY2028 EPS at $7.93 on projected FY2028 revenue of $9.91 billion. Extend that growth trajectory out another three years at an 8% compound annual growth rate, roughly in line with the company’s historical earnings growth before the Librela and guidance-cut era, and FY2031 EPS lands near $9.99.
Apply a 31x multiple to that number, the same multiple the market was willing to pay for ZTS earnings back when it traded near its all-time high, and you get a fair value of $309.55. That’s a re-rating case, not a growth miracle. It assumes the company simply returns to growing earnings at a reasonable clip and the market eventually stops pricing it like a broken business once it proves the dermatology and companion-animal declines have stabilized. It doesn’t require Librela litigation to disappear overnight or guidance cuts to stop entirely tomorrow. It requires the next several years of results to look more like the first four sections above (revenue growth, margin durability, cash generation) than the headline risk that’s dominated the last thirteen months.
Put the technical and fundamental cases side by side and they’re triangulating on almost the exact same number from two completely independent methods: a monthly Fibonacci extension at $309.42, and a bottom-up earnings and multiple build at $309.55. When a chart-based target and a fundamentals-based target land within a dollar of each other using two unrelated methodologies, that’s the kind of confluence worth paying attention to, even if it takes years to play out.
Thesis invalidation: what would prove this wrong
A real thesis isn’t complete without a real exit plan for being wrong. Amateurs focus on being right. Professionals focus on knowing exactly what would prove them wrong before they ever put capital at risk.
Technical invalidation: a sustained monthly close below the current $71.45 fifty-two-week low, especially if it comes with a decisive break of the multi-year uptrend line running off the 2013/2014 lows, would mean this isn’t basing above the 78.6% retracement anymore, it’s breaking through it. That turns a “deep pullback in an uptrend” into a genuine trend failure, and the entire Fibonacci extension framework this thesis leans on stops applying.
Fundamental invalidation: a sixth consecutive guidance cut, an acceleration (not stabilization) of the dermatology and companion-animal share losses, evidence that Simparica Trio and Apoquel losses are structural rather than cyclical, or a material escalation in the Librela litigation that results in a label change or product withdrawal would all directly undercut the earnings growth assumption this whole model depends on. If FY2028 consensus EPS estimates start getting revised down instead of up, the entire $309.55 fair-value build collapses with them, because that number only works if earnings actually compound from here.
Either signal on its own is a reason to reassess. Both together mean the thesis is dead and it’s time to move on, not average down out of stubbornness.
What this means for how you’d actually trade or hold it
None of this changes the fact that ZTS has already fallen 69% from its highs and could easily stay volatile, boring, or both for a long stretch before any of this plays out. A long-term thesis doesn’t mean an unmanaged position. It means sizing a position you can actually hold through more guidance cuts, more headline risk from the litigation, and more sideways chop without touching your stop or your sleep. If you’ve read our Risk Management Mastery series, this is the same drawdown math applied to a real ticker: a name that’s already down 69% doesn’t need to be “cheap” to keep falling further in the near term, and confused traders who bought the first bounce without a plan for another leg down are the ones who end up selling exactly at the point patience was required most.
Takeaway: The $310 target isn’t a prediction of a straight line higher. It’s a multi-year level where an independent technical extension and an independent fundamental re-rating happen to agree, sitting on top of a business that’s still growing revenue and generating serious cash while the market prices in more bad news than the numbers currently support. Whether or not ZTS ever prints that number, the lesson is the same one every beaten-down blue chip chart eventually teaches: have your invalidation plan written down before you have an opinion about the target. If it’s not repeatable, it’s not a strategy.
References
- Zoetis trims annual revenue forecast on muted demand for animal treatments – Reuters
- Zoetis forecasts strong 2026 profit, revenue as steady pet-medicine demand – Reuters
- Why is Zoetis stock collapsing today? – Investing.com
- Why Zoetis shares plummeted today – The Motley Fool
- Why is Zoetis stock sliding today? – Investing.com
- Zoetis cut its 2026 guide in Q2 earnings, the dermatology lead is the reason – TIKR
- Zoetis Q1 earnings lag estimates – Yahoo Finance
- Zoetis Inc. (ZTS) Investors: July 27, 2026 Deadline in Securities Fraud Class Action Lawsuit – Business Wire
- Judge drops class action lawsuit against Zoetis over Librela – dvm360
- Zoetis Inc. (ZTS) at Stifel Jaws & Paws Conference 2026 – Quartr
